499 related articles for article (PubMed ID: 31412729)
21. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
22. Unused potential of lipid-lowering therapy in very high-risk patients with atherosclerotic cardiovascular disease. A retrospective data analysis.
Pohl SB; Engelbertz C; Reinecke H; Malyar NM; Meyborg M; Brix TJ; Varghese J; Gebauer K
Nutr Metab Cardiovasc Dis; 2024 Jul; 34(7):1670-1680. PubMed ID: 38664125
[TBL] [Abstract][Full Text] [Related]
23. Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease.
Paraskevas KI; Gloviczki P; Antignani PL; Comerota AJ; Dardik A; Davies AH; Eckstein HH; Faggioli G; Fernandes E Fernandes J; Fraedrich G; Geroulakos G; Golledge J; Gupta A; Gurevich VS; Jawien A; Jezovnik MK; Kakkos SK; Knoflach M; Lanza G; Liapis CD; Loftus IM; Mansilha A; Nicolaides AN; Pini R; Poredos P; Proczka RM; Ricco JB; Rundek T; Saba L; Schlachetzki F; Silvestrini M; Spinelli F; Stilo F; Suri JS; Svetlikov AV; Zeebregts CJ; Chaturvedi S; Veith FJ; Mikhailidis DP
Prog Cardiovasc Dis; 2022; 73():41-47. PubMed ID: 35605696
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease.
Hess CN; Cannon CP; Beckman JA; Goodney PP; Patel MR; Hiatt WR; Mues KE; Orroth KK; Shannon E; Bonaca MP
J Am Coll Cardiol; 2021 Jun; 77(24):3016-3027. PubMed ID: 34140105
[TBL] [Abstract][Full Text] [Related]
25. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B
JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949
[TBL] [Abstract][Full Text] [Related]
26. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
De Ferrari GM; Perna GP; Nicosia A; Guasti L; Casu G; Cuccia C; Picco F; Strazzella C; Totaro R; Cercone S; Canullo L; Horack M; Lautsch D; Gitt AK; Di Biase M
J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):485-490. PubMed ID: 29917002
[TBL] [Abstract][Full Text] [Related]
27. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
[TBL] [Abstract][Full Text] [Related]
28. Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials.
Yang W; Cai X; Lin C; Lv F; Zhu X; Han X; Ji L
Medicine (Baltimore); 2022 Sep; 101(37):e30563. PubMed ID: 36123891
[TBL] [Abstract][Full Text] [Related]
29. Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?
Reklou A; Katsiki N; Karagiannis A; Athyros V
Curr Vasc Pharmacol; 2020; 18(1):38-42. PubMed ID: 30663570
[TBL] [Abstract][Full Text] [Related]
30. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY
J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
[TBL] [Abstract][Full Text] [Related]
32. Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified.
Baum SJ; Wade RL; Xiang P; Arellano J; Cerezo Olmos C; Nunna S; Chen CC; Carter CM; Desai NR
Ther Clin Risk Manag; 2019; 15():1325-1332. PubMed ID: 32009789
[TBL] [Abstract][Full Text] [Related]
33. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
Khan SU; Yedlapati SH; Lone AN; Hao Q; Guyatt G; Delvaux N; Bekkering GET; Vandvik PO; Riaz IB; Li S; Aertgeerts B; Rodondi N
BMJ; 2022 May; 377():e069116. PubMed ID: 35508321
[TBL] [Abstract][Full Text] [Related]
34. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
35. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
36. Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019.
Zheutlin AR; Derington CG; Herrick JS; Rosenson RS; Poudel B; Safford MM; Brown TM; Jackson EA; Woodward M; Reading S; Orroth K; Exter J; Virani SS; Muntner P; Bress AP
Circ Cardiovasc Qual Outcomes; 2022 Dec; 15(12):e008861. PubMed ID: 36252093
[TBL] [Abstract][Full Text] [Related]
37. Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients.
Navar AM; Kolkailah AA; Gupta A; Gillard KK; Israel MK; Wang Y; Peterson ED
Circ Cardiovasc Qual Outcomes; 2023 Aug; 16(8):533-543. PubMed ID: 37529931
[TBL] [Abstract][Full Text] [Related]
38. Association of Use and Dose of Lipid-Lowering Therapy Post Acute Myocardial Infarction With 5-Year Survival in Older Adults.
Fayol A; Schiele F; Ferrières J; Puymirat E; Bataille V; Tea V; Chamandi C; Albert F; Lemesle G; Cayla G; Weizman O; Simon T; Danchin N;
Circ Cardiovasc Qual Outcomes; 2024 May; 17(5):e010685. PubMed ID: 38682335
[TBL] [Abstract][Full Text] [Related]
39. Current status of lipid management in acute coronary syndrome.
Fujisue K; Tsujita K
J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
[TBL] [Abstract][Full Text] [Related]
40. Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy.
Khan SU; Khan MU; Riaz H; Raggi P; Valavoor S; Khan MZ; Kołodziejczak M; Khan MS; Krupica T; Alkhouli M; Navarese EP
Am J Cardiol; 2020 Mar; 125(5):727-734. PubMed ID: 31898964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]